182 related articles for article (PubMed ID: 35836207)
1. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Hu X; Li R; Li Q; Zang M; Yuan G; Chen J
BMC Infect Dis; 2022 Jul; 22(1):614. PubMed ID: 35836207
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
3. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study.
Yuan G; Li R; Li Q; Hu X; Ruan J; Fan W; Wang J; Huang W; Zang M; Chen J
Ann Transl Med; 2021 Sep; 9(18):1412. PubMed ID: 34733964
[TBL] [Abstract][Full Text] [Related]
4. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
[TBL] [Abstract][Full Text] [Related]
5. Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy.
Sun X; Hu D; Yang Z; Liu Z; Wang J; Chen J; Xu L; Zhou Z; Chen M; Zhang Y
J Hepatocell Carcinoma; 2020; 7():337-345. PubMed ID: 33294424
[TBL] [Abstract][Full Text] [Related]
6. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ
PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038
[TBL] [Abstract][Full Text] [Related]
7. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Yang Y; Wen F; Li J; Zhang P; Yan W; Hao P; Xia F; Bi F; Li Q
Liver Int; 2015 Sep; 35(9):2147-54. PubMed ID: 25676812
[TBL] [Abstract][Full Text] [Related]
8. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
[TBL] [Abstract][Full Text] [Related]
9. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
12. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Sato K; Inoue J; Akahane T; Kobayashi T; Takai S; Nakamura T; Sato T; Kimura O; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A
Tohoku J Exp Med; 2022 Nov; 258(4):277-285. PubMed ID: 36244758
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Suda G; Baba M; Yamamoto Y; Sho T; Ogawa K; Kimura M; Hosoda S; Yoshida S; Kubo A; Fu Q; Yang Z; Tokuchi Y; Kitagataya T; Maehara O; Ohnishi S; Yamada R; Ohara M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Suzuki K; Izumi T; Meguro T; Terashita K; Ito J; Kobayashi T; Tsunematsu I; Sakamoto N
J Med Virol; 2023 Feb; 95(2):e28452. PubMed ID: 36597900
[TBL] [Abstract][Full Text] [Related]
14. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
15. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors.
Yang Z; Guan R; Fu Y; Hu D; Zhou Z; Chen M; Zhang Y
Front Cell Infect Microbiol; 2024; 14():1336619. PubMed ID: 38415009
[TBL] [Abstract][Full Text] [Related]
19. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
20. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.
Liang Y; Zhong D; Zhang Z; Su Y; Yan S; Lai C; Yao Y; Shi Y; Huang X; Shang J
BMC Cancer; 2024 Mar; 24(1):291. PubMed ID: 38438842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
